NCI-H358 Cells

NCI-H358, also known as H-358 or NCIH358, is an epithelial-like cell line derived from a patient with bronchioalveolar carcinoma, a subtype of non-small cell lung cancer (NSCLC). These cells display ultrastructural characteristics typical of Clara cells, such as specific cytoplasmic features. NCI-H358 cells are particularly relevant in cancer research focused on NSCLC, especially for exploring the biology and treatment of lung adenocarcinomas.
This cell line is crucial for studying the effectiveness of therapies targeting the Epidermal Growth Factor Receptor (EGFR), as mutations in EGFR are a significant focus in the treatment of NSCLC. Additionally, NCI-H358 cells are valuable for investigating the role of KRAS mutations, which are prevalent in lung cancer and known to drive oncogenic activity. The study of these mutations in NCI-H358 cells helps to elucidate the molecular pathways involved in lung cancer progression and resistance to therapies.
The NCI-H358 cell line harbors a homozygous deletion of p53, a major tumor suppressor. The H358 lung cancer cell line is also used to assess the potential of novel therapeutic approaches, such as SOS1 PROTACs, aimed at targeting specific oncogenic pathways.
In summary, the NCI-H358 cell line, derived from bronchioalveolar carcinoma, is a vital tool in NSCLC research. It is instrumental for studying EGFR-targeted therapies and KRAS mutations’ role in lung cancer. Its application in cancer research extends to the development of new therapeutic strategies aimed at mitigating the effects of oncogenic mutations and improving patient outcomes in lung cancer.